X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CIPLA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CIPLA ASTRAZENECA PHARMA/
CIPLA
 
P/E (TTM) x 117.9 45.8 257.5% View Chart
P/BV x 16.8 4.0 420.2% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   CIPLA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
CIPLA
Mar-17
ASTRAZENECA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,285622 206.6%   
Low Rs634458 138.3%   
Sales per share (Unadj.) Rs189.6181.9 104.3%  
Earnings per share (Unadj.) Rs-0.212.9 -1.6%  
Cash flow per share (Unadj.) Rs3.829.3 13.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs68.6155.7 44.1%  
Shares outstanding (eoy) m25.00804.51 3.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.13.0 170.4%   
Avg P/E ratio x-4,712.742.0 -11,230.0%  
P/CF ratio (eoy) x249.618.4 1,354.6%  
Price / Book Value ratio x14.03.5 403.0%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m23,988434,516 5.5%   
No. of employees `0001.623.0 6.8%   
Total wages/salary Rs m1,60526,338 6.1%   
Avg. sales/employee Rs Th3,040.26,349.1 47.9%   
Avg. wages/employee Rs Th1,029.21,143.0 90.0%   
Avg. net profit/employee Rs Th-3.3449.3 -0.7%   
INCOME DATA
Net Sales Rs m4,740146,302 3.2%  
Other income Rs m922,287 4.0%   
Total revenues Rs m4,832148,589 3.3%   
Gross profit Rs m-13024,758 -0.5%  
Depreciation Rs m10113,229 0.8%   
Interest Rs m01,594 0.0%   
Profit before tax Rs m-13912,222 -1.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,798 0.3%   
Profit after tax Rs m-510,354 -0.0%  
Gross profit margin %-2.716.9 -16.2%  
Effective tax rate %-3.714.7 -24.9%   
Net profit margin %-0.17.1 -1.5%  
BALANCE SHEET DATA
Current assets Rs m2,72687,370 3.1%   
Current liabilities Rs m2,43533,081 7.4%   
Net working cap to sales %6.137.1 16.6%  
Current ratio x1.12.6 42.4%  
Inventory Days Days7487 84.8%  
Debtors Days Days4162 65.4%  
Net fixed assets Rs m1,035111,567 0.9%   
Share capital Rs m501,609 3.1%   
"Free" reserves Rs m942123,645 0.8%   
Net worth Rs m1,716125,254 1.4%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m4,156209,532 2.0%  
Interest coverage xNM8.7-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.10.7 163.3%   
Return on assets %-0.15.7 -2.1%  
Return on equity %-0.38.3 -3.6%  
Return on capital %08.5 0.0%  
Exports to sales %5.734.2 16.7%   
Imports to sales %6.58.3 77.5%   
Exports (fob) Rs m27050,050 0.5%   
Imports (cif) Rs m30612,203 2.5%   
Fx inflow Rs m37551,066 0.7%   
Fx outflow Rs m47017,678 2.7%   
Net fx Rs m-9633,388 -0.3%   
CASH FLOW
From Operations Rs m-823,824 -0.0%  
From Investments Rs m-146-13,127 1.1%  
From Financial Activity Rs m862-13,239 -6.5%  
Net Cashflow Rs m709-2,478 -28.6%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 0.3 12.2 2.5%  
FIIs % 15.7 23.7 66.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 9.1 26.2 34.7%  
Shareholders   12,856 161,166 8.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  PFIZER  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 23, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS